

## AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions and listings of claims in the application:

### LISTING OF CLAIMS:

1. **(currently amended):** A medical composition, comprising:

a peptide-capable of being labeled with a metal and

a basic organic compound acceptable as a pharmaceutical additive wherein the basic organic compound is a basic amino acid or a basic compound having an imidazole ring, wherein the peptide-capable of being labeled with a metal is a compound represented by chemical formula (1):



wherein in formula (1),

Z represents a protecting group for an amino group;

Y represents Met or Nle;

in  $(X)_n$ , X represents a spacer consisting of one or more amino acids or a compound capable of being organically synthesized, and n represents 1 or 0;

in  $(NH_2)_m$ ,  $NH_2$  represents an amide group serving as a protecting group for an  $\alpha$ -carboxyl group of Lys, and m represents 1 or 0; and

in  $\epsilon-(R)-o-(T)l-U$ , R represents Ser or Thr bound via amide bond with an  $\epsilon$ -amino group of Lys;

o represents 1 or 0;

~~T represents a spacer consisting of one or more amino acids or a compound capable of being organically synthesized, I represents 1 or 0, and U represents a group capable of being labeled with a metal,~~

~~provided that X and T may be identical or different selected from the group consisting of N-formyl-Nlc-Lcu-Phe-Nlc-Tyr-Lys(NH<sub>2</sub>)-ε(-Ser-Cys-Gly-Asn) (SEQ ID NO:1), N-formyl-Nlc-Lcu-Phe-Nlc-Tyr-Lys(NH<sub>2</sub>)-ε(-Ser-Cys-Gly-Asp) (SEQ ID NO:2), N-formyl-Nlc-Lcu-Phe-Nlc-Tyr-Lys-ε(-Ser-Cys-Asp-Asp) (SEQ ID NO:3), N-formyl-Nlc-Lcu-Phe-Nlc-Tyr-Lys(NH<sub>2</sub>)-ε(-Ser-D-Arg-Asp-Cys-Asp-Asp) (SEQ ID NO:4), N-formyl-Nlc-Lcu-Phe-Nlc-Tyr-Lys(NH<sub>2</sub>)-ε(-Ser-D-Arg-diethylenetriaminepentaacetic acid (DTPA)) (SEQ ID NO:5), N-formyl-Met-Lcu-Phe-Lys-ε(-Asp-Asp-mercaptoacetyl) (SEQ ID NO:7), N-formyl-Met-Lcu-Phe-Lys-ε(-Gly-Asp-mercaptoacetyl) (SEQ ID NO:8), and N-formyl-Met-Lcu-Phe-Lys-ε(-Gly-Gly-mercaptoacetyl) (SEQ ID NO:9).~~

**2-3. (canceled).**

**4. (previously presented):** The medical composition according to claim 1, wherein the basic amino acid is one or more members selected from arginine, histidine, and lysine.

**5. (previously presented):** The medical composition according to claim 1, wherein the basic compound having an imidazole ring is imidazole.

6. **(currently amended):** The medical composition according to claim 1, wherein the peptide ~~capable of being~~ labeled with a metal is a peptide available as an active ingredient in a diagnostic drug or a pharmaceutical drug for therapeutic use.

7. **(currently amended):** The medical composition according to claim 1, wherein the peptide ~~capable of being~~ labeled with a metal has 30 or less amino acid residues or a molecular weight of 4500 or less.

8. **(currently amended):** The medical composition according to claim 1, wherein the peptide ~~capable of being~~ labeled with a metal is a leukocyte-binding compound.

9. **(canceled).**

10. **(canceled).**

11. **(canceled).**

12. **(canceled).**

13. **(canceled).**

**14. (previously presented):** The medical composition according to claim 1, wherein the composition further comprises one or more additives selected from a reductant, pH adjuster, surfactant, hydrophilic organic solvent, and stabilizer.

**15. (previously presented):** A freeze-dried medical composition characterized in that the composition is obtained by freeze-drying a medical composition according to claim 1.

**16. (currently amended):** A medical preparation characterized in that the preparation is obtained by labeling, with a metal, a peptide ~~capable of being~~ labeled with a metal in a medical composition according to claim 1.

**17. (original):** The medical preparation according to claim 16, wherein the metal is a radioactive metal or paramagnetic metal.

**18. (original):** The medical preparation according to claim 17, wherein the radioactive metal is selected from Tc-99m, In-111, Ga-67, Y-90, Sn-117m, Sm-153, Re-186, and Re-188.

**19. (original):** The medical preparation according to claim 17, wherein the paramagnetic metal is selected from Gd, Fe, Mn, Cu, and Dy.

**20. (withdrawn—currently amended):** A method for labeling, with a metal, a peptide ~~capable of being~~ labeled with a metal, comprising the steps of:

dissolving the peptide in an aqueous solvent of a basic organic compound; and then labeling the resulting product with a metal.

21. **(withdrawn—currently amended):** The metal-labeling method according to claim 20, wherein the peptide ~~capable of being~~ labeled with a metal is a peptide insoluble or poorly soluble in an aqueous solvent.

22. **(withdrawn):** The metal-labeling method according to claim 20, wherein the basic organic compound is a basic amino acid or a basic compound having an imidazole ring.

23. **(withdrawn):** The metal-labeling method according to claim 22, characterized in that the basic amino acid is one or more members selected from arginine, histidine, and lysine.

24. **(withdrawn):** The metal-labeling method according to claim 22, wherein the basic compound having an imidazole ring is imidazole.

25. **(withdrawn):** The metal-labeling method according to claim 20, characterized in that the metal is a radioactive metal or paramagnetic metal.

26. **(withdrawn):** The metal-labeling method according to claim 25, wherein the radioactive metal is selected from Tc-99m, In-111, Ga-67, Y-90, Sn-117m, Sm-153, Re-186, and Re-188.

**27. (withdrawn):** The metal-labeling method according to claim 25, wherein the paramagnetic metal is selected from Gd, Fe, Mn, Cu, and Dy.

**28. (withdrawn):** A method for producing a medical preparation comprising a metal-labeled peptide, characterized by using a metal-labeling method according to claim 20.